Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2021

View Archived Issues

Linking antiphospholipid antibodies to autoimmunity

Lipid dysregulation gives information on Parkinson's

Immune system, treatment, in kidney cancer

Moderna initiates phase I study of its next-generation COVID-19 vaccine, mRNA-1283

Multimorbid diseases cluster in predictable ways: study

Pliant completes phase I study of PLN-1474 and transfers the candidate to Novartis

First patients dosed in global phase I study of ADG-126

First patient dosed in phase I study of emricasan in mild symptomatic COVID-19

Arbutus receives regulatory approval for phase Ia/Ib trial of AB-836 in chronic HBV infection

Galmed initiates dosing in first-in-human phase I trial of Amilo-5MER

FDA clears IND for phase II study of CYTO-205 as treatment of mild COVID-19

AB-205 eliminates oral and gastrointestinal SRRT in adults undergoing HDT-AHCT

UCB describes new antimalarial compounds

KalVista Pharmaceuticals discovers FXIIa inhibitors

Otsuka Pharmaceutical, Taiho Pharmaceutical patent PTPN11 inhibitors

New anti-SIRP-alpha antibodies described by Elpiscience BioPharma

First-in-human results presented for R-552 in healthy adults

Biohaven Therapeutics identifies compounds targeting TDP-43

Study reveals dose finding for gevokizumab in oncology

THCVHS shows no signs of eye irritation in in vitro assay

French clearance for first-in-human study of PEP-010 in advanced solid tumors

Phase Ib data with VS-01 support advancement to phase IIa for acute on chronic liver failure

Corat gains clearances to begin phase Ib/II trial of COR-101 for COVID-19

HTI vaccines show promise for virus control without ART in patients with early HIV infection

Clinical trial collaboration supports new phase II study of Tabrecta and Nerlynx in breast cancer

Annovis reports phase IIa interim data on ANVS-401 in Parkinson's patients

MaaT reports phase II topline data on MaaT-013 in steroid-refractory GI acute GvHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...